Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Antibiotics for irritable bowel syndrome: rationale and current evidence.

Sachdev AH, Pimentel M.

Curr Gastroenterol Rep. 2012 Oct;14(5):439-45. doi: 10.1007/s11894-012-0284-2. Review.

PMID:
22945316
2.

Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1.

Pimentel M.

Am J Gastroenterol. 2010 Apr;105(4):718-21. doi: 10.1038/ajg.2009.678.

PMID:
20372119
3.

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome.

Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M.

Gut. 2007 Jun;56(6):802-8. Epub 2006 Dec 5.

4.

Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective.

Spiegel BM.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):461-9; quiz e59. doi: 10.1016/j.cgh.2011.02.030. Epub 2011 Mar 11. Review.

PMID:
21397724
5.

Bacterial concepts in irritable bowel syndrome.

Lin HC, Pimentel M.

Rev Gastroenterol Disord. 2005;5 Suppl 3:S3-9. Review.

PMID:
17713456
6.

Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.

Ghoshal UC, Srivastava D, Ghoshal U, Misra A.

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):753-60. doi: 10.1097/MEG.0000000000000122.

PMID:
24849768
7.

Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth.

Lee HR, Pimentel M.

Curr Gastroenterol Rep. 2006 Aug;8(4):305-11. Review.

PMID:
16836942
8.

[Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome].

Łokieć K, Klupińska G, Walecka-Kapica E, Błońska A.

Pol Merkur Lekarski. 2014 May;36(215):307-10. Polish.

PMID:
24964506
9.

Irritable bowel syndrome and small intestinal bacterial overgrowth.

Yamini D, Pimentel M.

J Clin Gastroenterol. 2010 Nov-Dec;44(10):672-5. doi: 10.1097/MCG.0b013e3181ef3476. Review.

PMID:
20838236
10.

Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.

Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitraşcu DL.

Rom J Intern Med. 2013 Jul-Dec;51(3-4):143-7.

PMID:
24620626
11.

Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.

Pimentel M.

Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:37-49. doi: 10.1111/apt.13437. Review.

PMID:
26618924
12.

Inflammation and microflora.

Pimentel M, Chang C.

Gastroenterol Clin North Am. 2011 Mar;40(1):69-85. doi: 10.1016/j.gtc.2010.12.010. Review.

PMID:
21333901
13.

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis.

Ford AC, Spiegel BM, Talley NJ, Moayyedi P.

Clin Gastroenterol Hepatol. 2009 Dec;7(12):1279-86. doi: 10.1016/j.cgh.2009.06.031. Epub 2009 Aug 12. Review.

PMID:
19602448
14.

The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment.

Vanner S.

Gut. 2008 Sep;57(9):1315-21. doi: 10.1136/gut.2007.133629. Epub 2008 Feb 4. Review. No abstract available.

PMID:
18250127
15.

[Microbiota and irritable bowel syndrome].

Ducrotté P.

Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S52-6. doi: 10.1016/S0399-8320(10)70021-X. French.

16.
17.

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.

Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A.

World J Gastroenterol. 2009 Jun 7;15(21):2628-31.

18.

[Bacterial overgrowth syndrome].

Stein JM, Schneider AR.

Z Gastroenterol. 2007 Jul;45(7):620-8. Review. German.

PMID:
17620228
19.

[Postinfectious irritable bowel syndrome].

Döbrönte Z, Lakner L, Sarang K.

Orv Hetil. 2006 Oct 29;147(43):2077-80. Review. Hungarian.

PMID:
17297754
20.

Small intestine bacterial overgrowth in patients with irritable bowel syndrome.

Carrara M, Desideri S, Azzurro M, Bulighin GM, Di Piramo D, Lomonaco L, Adamo S.

Eur Rev Med Pharmacol Sci. 2008 May-Jun;12(3):197-202.

PMID:
18700692

Supplemental Content

Support Center